```html

Keratitis Bullosa – A Comprehensive Medical Guide

Overview

Keratitis bullosa (also called bullous keratopathy or bullous corneal ulcer) is an inflammatory eye disorder characterized by the formation of fluid‑filled blisters (bullae) on the corneal surface. The condition can arise from infection, autoimmune disease, trauma, or exposure to certain chemicals or medications. When the epithelial layer of the cornea is compromised, tears cannot glide smoothly, leading to painful swelling and, if untreated, scarring that threatens vision.

The disease can affect anyone but is most common in:

• Adults aged 20‑60, especially those with a history of ocular surgery or contact‑lens wear.
• Patients with systemic autoimmune disorders such as rheumatoid arthritis, lupus, or Stevens‑Johnson syndrome.
• Individuals living in regions with limited access to clean water or proper eye protection (e.g., agricultural workers).

Exact prevalence is difficult to determine because bullous keratopathy is often reported as a complication of other eye conditions. In the United States, corneal ulcerations (the broader category that includes bullous keratopathy) affect roughly 1.5–2.0 per 10,000 people each year, with bullous forms comprising an estimated 10‑15 % of those cases <sup>[1]</sup>. Worldwide, the burden is higher in low‑income countries where infectious keratitis is more common.

Symptoms

Symptoms may develop gradually over days or appear suddenly after an insult to the eye. The hallmark is the presence of “bullae” – tiny, fluid‑filled blisters on the cornea. Common signs and symptoms include:

• Redness (hyperemia): The white part of the eye looks pink or violet.
• Severe pain or burning sensation: Often described as gritty, as if sand is in the eye.
• Photophobia: Heightened sensitivity to light.
• Blurred or decreased vision: Vision may fluctuate with blinking.
• Tearing (epiphora): Excessive watery discharge.
• Foreign‑body sensation: The feeling that something is stuck in the eye.
• Visible corneal bullae: Tiny translucent vesicles seen with a slit‑lamp exam; they may coalesce into larger blisters that can rupture.
• Sticky eyelids: When bullae rupture, the exposed corneal surface adheres to the eyelid, causing further pain.
• Discharge: In infectious cases, a purulent (pus‑filled) discharge may be present.
• Eye swelling (periorbital edema): In severe inflammation, the tissues around the eye may become swollen.

Causes and Risk Factors

Keratitis bullosa is not a single disease; it is a manifestation of several underlying insults to the cornea. The most common causes are:

Infectious agents

• Bacterial: Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
• Fungal: Fusarium, Aspergillus, and Candida species.
• Acanthamoeba: Often linked to poor contact‑lens hygiene.
• Viral: Herpes simplex virus (HSV) and varicella‑zoster virus (VZV) can produce dendritic ulcers that later become bullous.

Non‑infectious triggers

• Autoimmune diseases: Rheumatoid arthritis, pemphigoid, ocular cicatricial pemphigoid.
• Chemical burns: Alkali or acid exposure.
• Trauma: Corneal abrasions, foreign bodies.
• Medications: Topical non‑steroidal anti‑inflammatory drugs (NSAIDs), long‑term topical steroids, or preservatives in eye drops.
• Surgical complications: Endothelial cell loss after cataract surgery or corneal transplant can lead to chronic edema and bullae formation.

Risk factors

• Contact‑lens wear, especially overnight extended wear.
• Dry eye disease or insufficient tear film.
• Immunosuppression (e.g., diabetes, HIV, systemic steroids).
• Previous corneal surgery.
• Occupational exposure to dust, chemicals, or organic matter.

Diagnosis

Prompt, accurate diagnosis is essential to prevent permanent corneal scarring. Diagnosis combines a detailed history, a thorough eye examination, and targeted laboratory testing.

Clinical evaluation

• History taking: Onset, exposure risks (contact lenses, trauma), systemic illnesses, medication use.
• Visual acuity test: Determines the impact on sight.
• Slit‑lamp microscopy: Gold‑standard for visualizing corneal bullae, epithelial defects, stromal infiltrates, and hypopyon (pus in the anterior chamber).
• Fluorescein staining: Highlights epithelial breakdown; bullae appear as dark “droplets” surrounded by bright green staining.
• Intra‑ocular pressure (IOP) measurement: Elevated pressure can coexist in severe inflammation.

Laboratory tests

• Corneal scrapings: Obtained with a sterile blade and cultured on bacterial, fungal, and Acanthamoeba media.
• Polymerase chain reaction (PCR): Detects viral DNA (HSV, VZV) quickly.
• Serology: When autoimmune disease is suspected (e.g., ANA, rheumatoid factor).

Imaging

• Anterior segment optical coherence tomography (AS‑OCT): Provides cross‑sectional images of bullae depth.
• Confocal microscopy: Allows in‑vivo visualization of pathogens, especially Acanthamoeba cysts.

Treatment Options

Treatment is tailored to the underlying cause and the severity of the bullae. Goals are to eradicate infection (if present), control inflammation, promote epithelial healing, and protect the cornea from further damage.

Medication‑based therapies

• Antibiotics: Broad‑spectrum topical drops (e.g., moxifloxacin, tobramycin) until culture results guide targeted therapy.
• Antifungals: Natamycin 5 % suspension or voriconazole eye drops for fungal isolates.
• Antivirals: Topical trifluridine or oral acyclovir for HSV; oral valacyclovir for VZV.
• Acanthamoeba agents: Combination of chlorhexidine 0.02 % and polyhexamethylene biguanide (PHMB) 0.02 %.
• Corticosteroids: Used cautiously after infection control; prednisolone acetate 1 % to dampen immune‑mediated inflammation.
• Cyclosporine or lifitegrast: For severe dry eye contributing to epithelial breakdown.

Procedural interventions

• Debridement: Mechanical removal of loose epithelium and bullae under aseptic conditions to allow medication penetration.
• Bandage contact lens (BCL): Silicone hydrogel lenses protect the cornea, reduce pain, and promote re‑epithelialization.
• Amniotic membrane transplantation (AMT): Provides a biologic scaffold, reduces inflammation, and accelerates healing in refractory cases.
• Therapeutic keratoplasty: Partial or full‑thickness corneal transplant when scarring threatens vision.
• Phototherapeutic keratectomy (PTK): Excimer laser removal of superficial opacities and bullae.

Lifestyle & supportive measures

• Artificial tears (preservative‑free) every 2–4 hours.
• Warm compresses 5 minutes, 3–4 times daily to improve tear film.
• Stop contact‑lens wear until the cornea fully heals.
• Protect the eye with sunglasses outdoors to reduce UV‑induced inflammation.

Living with Keratitis Bullosa

Even after the acute episode resolves, patients may need ongoing care to prevent recurrence and preserve vision.

• Adhere to medication schedules: Missing doses can allow infection to flare.
• Maintain eyelid hygiene: Warm lid scrubs reduce bacterial load.
• Use preservative‑free lubricants: Preservatives can irritate a healing cornea.
• Follow up regularly: At least every 1–2 weeks initially; later, every 3–6 months or as directed.
• Monitor vision changes: Any new blurring, floaters, or light flashes warrants prompt evaluation.
• Protect the eye during activities: Safety goggles for sports, gardening, or work with chemicals.
• Nutrition: Adequate omega‑3 fatty acids (e.g., fish oil) support tear quality.
• Manage systemic disease: Keep rheumatoid arthritis, diabetes, or other conditions well‑controlled with your primary physician.

Prevention

Many cases of keratitis bullosa are preventable with simple habits:

• Proper contact‑lens care: Wash hands, use recommended solutions, replace lenses as scheduled, and avoid overnight wear unless approved.
• Eye protection: Wear goggles in dusty, windy, or chemical environments.
• Prompt treatment of minor corneal abrasions: Even tiny scratches can become portals for infection.
• Control dry eye: Use humidifiers, lubricating drops, and treat meibomian gland dysfunction.
• Vaccination: Varicella and herpes zoster vaccines reduce the risk of viral keratitis.
• Regular eye exams: Early detection of ocular surface disease allows interventions before bullae form.

Complications

If left untreated or inadequately managed, keratitis bullosa can lead to serious sequelae:

• Corneal scarring (stromal opacity): Permanent visual impairment.
• Corneal neovascularization: New blood vessels reduce corneal clarity.
• Persistent epithelial defects: Chronic pain and risk of infection.
• Endophthalmitis: Extension of infection into the interior of the eye – a sight‑threatening emergency.
• Glaucoma: Inflammation can raise intra‑ocular pressure.
• Loss of vision: In severe cases, vision may deteriorate to legal blindness.

When to Seek Emergency Care

---

**References**

1. American Academy of Ophthalmology. “Corneal Ulcer.” AAO, 2023. https://www.aao.org/eye-health/diseases/corneal-ulcer
2. Mayo Clinic. “Keratitis.” Mayo Clinic, 2022. https://www.mayoclinic.org/diseases-conditions/keratitis
3. World Health Organization. “Prevention of Blindness from Corneal Opacities.” WHO, 2021.
4. Cleveland Clinic. “Contact Lens‑Related Eye Infections.” Cleveland Clinic, 2024.
5. National Eye Institute (NEI). “Corneal Disease: Facts and Statistics.” NIH, 2023.

```